{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:37:31Z","timestamp":1759412251340},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"12","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jom-2022-0070_abs_001\">\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Vaccination status has been shown to be linked to patient-centered outcomes in those with COVID-19. However, minimal data have explored the relationship between vaccination status and representation rates after receiving monoclonal antibodies (MABs) the Delta strain of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in a community setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jom-2022-0070_abs_002\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The authors sought to determine if there was a difference in patient-centered outcomes between those who were vaccinated and unvaccinated after the administration of casirivimab\/imdevimab for mild-to-moderate COVID-19 during the time when the Delta strain was most prevalent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jom-2022-0070_abs_003\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A convenience sample of consecutive adults given casirivimab\/imdevimab at either an outpatient infusion center or within the emergency department (ED) were included in analysis. Patient demographics, authorized-use qualifiers from the emergency use authorization (EUA), baseline vital signs at the time of infusion, representation rates to a healthcare provider within the hospital\u2019s network, and any admissions to the hospital following infusion were all collected from the patient\u2019s electronic medical record. Vaccination status was confirmed in both the patient\u2019s electronic medical record and the Arizona State Immunization Information System (ASIIS). Analysis was conducted utilizing descriptive statistics, the Mann\u2013Whitney U test for continuous data, and the chi-squared analysis for nominal data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jom-2022-0070_abs_004\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 743 patients were included in the study, with 585 being unvaccinated and 158 being vaccinated at the time of administration. Those in the vaccinated group were more likely to be older (60.0 vs. 55.0\u00a0years; p&lt;0.001) and to have a history of diabetes (18.4% vs. 11.3%; p=0.02), hypertension (39.9% vs. 28.5%; p=0.006), immunosuppression (7.0% vs. 1.4%; p&lt;0.001), and chronic kidney disease (7.0% vs. 3.4%; p=0.05). In the entire sample, 105 (14.1%) patients had an unexpected return visit to either the ED or urgent care at 28\u00a0days, with 17 (2.3%) requiring hospitalization. Patients who were vaccinated were more likely to represent for care after casirivimab\/imdevimab infusion (20.3% vs. 12.5%; p=0.01), but no difference was noted in hospitalization rates between the two groups (18.8% vs. 15.1%; p=0.15).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jom-2022-0070_abs_005\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>MAB therapy with casirivimab\/imdevimab for the outpatient treatment of mild-to-moderate COVID-19 was associated with a low rate of hospitalization. However, those who were vaccinated were more likely to present for unexpected return care at either the ED or urgent care within 28\u00a0days of the initial infusion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jom-2022-0070","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T03:08:31Z","timestamp":1663643311000},"page":"635-640","source":"Crossref","is-referenced-by-count":4,"title":["Casirivimab\/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital"],"prefix":"10.1515","volume":"122","author":[{"given":"Erika","family":"Keshishian","sequence":"first","affiliation":[{"name":"Pacific Northwest University of Health Sciences College of Osteopathic Medicine , Yakima , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Kuge","sequence":"additional","affiliation":[{"name":"Rocky Vista University College of Osteopathic Medicine , Parker , CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Memmott","sequence":"additional","affiliation":[{"name":"Pacific Northwest University of Health Sciences College of Osteopathic Medicine , Yakima , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Hasenbalg","sequence":"additional","affiliation":[{"name":"Pacific Northwest University of Health Sciences College of Osteopathic Medicine , Yakima , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakiya","family":"Belford","sequence":"additional","affiliation":[{"name":"Pacific Northwest University of Health Sciences College of Osteopathic Medicine , Yakima , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Matlock","sequence":"additional","affiliation":[{"name":"Pacific Northwest University of Health Sciences College of Osteopathic Medicine , Yakima , WA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Schritter","sequence":"additional","affiliation":[{"name":"Department of Nursing , Kingman Regional Medical Center , Kingman , AZ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geovar","family":"Agbayani","sequence":"additional","affiliation":[{"name":"Department of Graduate Medical Education , Kingman Regional Medical Center , Kingman , AZ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyson","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Kingman Regional Medical Center , Kingman , AZ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Santarelli","sequence":"additional","affiliation":[{"name":"Department of Graduate Medical Education , Kingman Regional Medical Center , Kingman , AZ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ashurst","sequence":"additional","affiliation":[{"name":"Department of Graduate Medical Education , Kingman Regional Medical Center , Kingman , AZ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"2022111808534466085_j_jom-2022-0070_ref_001","doi-asserted-by":"crossref","unstructured":"Del Rio, C, Malani, PN, Omer, SB. Confronting the Delta variant of SARS-CoV-2, summer 2021. JAMA 2021;326:1001\u20132. https:\/\/doi.org\/10.1001\/jama.2021.14811.","DOI":"10.1001\/jama.2021.14811"},{"key":"2022111808534466085_j_jom-2022-0070_ref_002","unstructured":"Twohig, KA, Nyberg, T, Zaidi, A, Thelwall, S, Sinnathamby, MA, Aliabadi, S, et al.. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis 2022;22:35\u201342. https:\/\/doi.org\/10.1016\/S1473-3009(21)00475-8."},{"key":"2022111808534466085_j_jom-2022-0070_ref_003","doi-asserted-by":"crossref","unstructured":"Lin, L, Liu, Y, Tang, X, He, D. The disease severity and clinical outcomes of the SARS-CoV-2 variants of concern. Front Public Health 2021;9:9775224. https:\/\/doi.org\/10.3389\/fpubh.2021.775224.","DOI":"10.3389\/fpubh.2021.775224"},{"key":"2022111808534466085_j_jom-2022-0070_ref_004","unstructured":"Centers for Disease Control and Prevention. COVID data tracker. 2022. Available from: https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-total-admin-rate-total."},{"key":"2022111808534466085_j_jom-2022-0070_ref_005","doi-asserted-by":"crossref","unstructured":"Kow, CS, Ramachandram, DS, Hasan, SS. The use of neutralizing monoclonal antibodies and risk of hospital admission ad mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Immunopharmacol Immunotoxicol 2022;44:28\u201334. https:\/\/doi.org\/10.1080\/08923973.2021.1993894.","DOI":"10.1080\/08923973.2021.1993894"},{"key":"2022111808534466085_j_jom-2022-0070_ref_006","doi-asserted-by":"crossref","unstructured":"Lin, WT, Hung, SH, Lai, CC, Wang, CY, Chen, CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials. J Med Virol 2022;94:2222\u20139. https:\/\/doi.org\/10.1002\/jmv.27623.","DOI":"10.1002\/jmv.27623"},{"key":"2022111808534466085_j_jom-2022-0070_ref_007","doi-asserted-by":"crossref","unstructured":"Weinreich, D, Sivapalasingman, S, Norton, T, Ali, S, Gao, H, Bhore, R, et al.. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med 2021;384:238\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2035002.","DOI":"10.1056\/NEJMoa2035002"},{"key":"2022111808534466085_j_jom-2022-0070_ref_008","unstructured":"Translational Genomics Research Institute. The Arizona COVID-19 sequencing dashboard. 2022. Available from: https:\/\/pathogen.tgen.org\/covidseq-tracker\/arizona_trends.html [Accessed 21 Jun 2022]."},{"key":"2022111808534466085_j_jom-2022-0070_ref_009","doi-asserted-by":"crossref","unstructured":"Wilhelm, A, Toptan, T, Pallas, C, Wolf, T, Goetsch, U, Gottschalk, R, et al.. Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K\/E484Q. Viruses 2021;13:1693. https:\/\/doi.org\/10.3390\/v13091693.","DOI":"10.3390\/v13091693"},{"key":"2022111808534466085_j_jom-2022-0070_ref_010","doi-asserted-by":"crossref","unstructured":"Bierle, DM, Ganesh, R, Tulledge-Scheitel, S, Hanson, SN, Arndt, LL, Wilker, CG, et al.. Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individual with high-risk comorbidities. J Infect Dis 2022;225:598\u2013602. https:\/\/doi.org\/10.1093\/infdis\/jiab570.","DOI":"10.1093\/infdis\/jiab570"},{"key":"2022111808534466085_j_jom-2022-0070_ref_011","doi-asserted-by":"crossref","unstructured":"Bierle, DM, Ganesh, R, Razonable, RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. J Clin Virol 2021;145:105026. https:\/\/doi.org\/10.1016\/j.jcv.2021.105026.","DOI":"10.1016\/j.jcv.2021.105026"},{"key":"2022111808534466085_j_jom-2022-0070_ref_012","doi-asserted-by":"crossref","unstructured":"Zitek, T, Jodoin, K, Kheradia, T, Napolillo, R, Dalley, MT, Quenzer, F, et al.. Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19. Am J Emerg Med 2022;56:370\u20131. https:\/\/doi.org\/10.1016\/j.ajem.2021.10.044.","DOI":"10.1016\/j.ajem.2021.10.044"},{"key":"2022111808534466085_j_jom-2022-0070_ref_013","doi-asserted-by":"crossref","unstructured":"Ash, J, Leavitt, R, Dietrich, T, Schritter, S, Wells, J, Santarelli, A, et al.. Real world utilization of REGEN-COV2 at a community hospital. Am J Emerg Med 2021;50:129\u201331. https:\/\/doi.org\/10.1016\/j.ajem.2021.07.050.","DOI":"10.1016\/j.ajem.2021.07.050"},{"key":"2022111808534466085_j_jom-2022-0070_ref_014","doi-asserted-by":"crossref","unstructured":"Weinreich, DM, Sivapalasingam, S, Norton, T, Ali, S, Gao, H, Bhore, R, et al.. REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med 2021;385:e81. https:\/\/doi.org\/10.1056\/NEJMoa2108163.","DOI":"10.1056\/NEJMoa2108163"},{"key":"2022111808534466085_j_jom-2022-0070_ref_015","doi-asserted-by":"crossref","unstructured":"Copin, R, Baum, A, Wloga, E, Pascal, KE, Giordano, S, Fulton, BO, et al.. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 2021;184:3949\u201361. https:\/\/doi.org\/10.1016\/j.cell.2021.06.002.","DOI":"10.1016\/j.cell.2021.06.002"},{"key":"2022111808534466085_j_jom-2022-0070_ref_016","doi-asserted-by":"crossref","unstructured":"Johnson, AG, Amin, AB, Ali, AR, Hoots, B, Cadwell, BL, Arora, S, et al.. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence\u00a0\u2013 25 U.S. Jurisdictions, April 4\u00a0\u2013 December 25, 2021. MMWR. Morb Mortal Wkly Rep 2022;71:132\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7104e2.","DOI":"10.15585\/mmwr.mm7104e2"},{"key":"2022111808534466085_j_jom-2022-0070_ref_017","doi-asserted-by":"crossref","unstructured":"Bahl, A, Johnson, S, Maine, G, Garcia, MH, Nimmagadda, S, Qu, L, et al.. Vaccination reduces need for emergency care in breakthrough COVID-19 infections: a multicenter cohort study. Lancet Reg Health Am 2021;4:100065. https:\/\/doi.org\/10.1016\/j.lana.2021.100065.","DOI":"10.1016\/j.lana.2021.100065"},{"key":"2022111808534466085_j_jom-2022-0070_ref_018","doi-asserted-by":"crossref","unstructured":"Bergwerk, M, Gonen, T, Lustig, Y, Amit, S, Lipsitch, M, Cohen, C, et al.. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2109072.","DOI":"10.1056\/NEJMoa2109072"},{"key":"2022111808534466085_j_jom-2022-0070_ref_019","doi-asserted-by":"crossref","unstructured":"Chau, NVV, Ngoc, NM, Nguyet, LA, Quang, VM, Ny, NTH, Khoa, DB, et al.. An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinialMedicine 2021;41:101143. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101143.","DOI":"10.1016\/j.eclinm.2021.101143"},{"key":"2022111808534466085_j_jom-2022-0070_ref_020","doi-asserted-by":"crossref","unstructured":"Bogart, LM, Ojikutu, BO, Tyagi, K, Klein, DJ, Mutchler, MG, Dong, L, et al.. COVID-19 related medical mistrust, health impacts, and potential vaccine hesitancy among black Americans living with HIV. J Acquir Immune Defic Syndr 2021;86:200\u20137. https:\/\/doi.org\/10.1097\/QAI.0000000000002570.","DOI":"10.1097\/QAI.0000000000002570"},{"key":"2022111808534466085_j_jom-2022-0070_ref_021","doi-asserted-by":"crossref","unstructured":"LaVeist, T, Isaac, L, Williams, K. Mistrust of healthcare organizations is associated with underutilization of health services. Health Serv Res 2009;44:2093\u2013105. https:\/\/doi.org\/10.1111\/j.1475-6773.2009.01017.x.","DOI":"10.1111\/j.1475-6773.2009.01017.x"},{"key":"2022111808534466085_j_jom-2022-0070_ref_022","doi-asserted-by":"crossref","unstructured":"Jaiswal, J, Halkitis, P. Towards a more inclusive and dynamic understanding of medical mistrust informed by science. Behav Med 2019;45:79\u201385. https:\/\/doi.org\/10.1080\/08964289.2019.1619511.","DOI":"10.1080\/08964289.2019.1619511"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2022-0070\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2022-0070\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T08:54:34Z","timestamp":1668761674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jom-2022-0070\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,9,14]]},"published-print":{"date-parts":[[2022,11,18]]}},"alternative-id":["10.1515\/jom-2022-0070"],"URL":"https:\/\/doi.org\/10.1515\/jom-2022-0070","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}